Nüks Epitelyal Over Kanserinde Platin Duyarlılığının Klinik Yorumu ve Tedavi Seçimi

Yazarlar

Evrican Zin Güzel

Özet

Over kanseri, ilk tedaviye yanıt alınmasına karşın özellikle ileri evrede sık nüks eden bir hastalıktır. İleri evre yüksek dereceli epitelyal over kanserinde hastaların %70’e varan bölümünde ilk üç yıl içinde nüks gelişir. Nüks eden hastalıkta ikincil cerrahi, yeniden platin kullanımı, platin dışı kemoterapi, bevacizumab ve biyobelirtece dayalı tedaviler arasından seçim yapılır. Güncel kılavuzlarda bu seçim, yalnızca altı aylık platinsiz aralığa dayanan duyarlı/dirençli etiketlerinden çok, hastanın platinin yeniden kullanımına uygun olup olmadığına dayanır. Önceki platin yanıtı, tedavi sırasındaki veya sonrasındaki progresyonun niteliği, histolojik alt tip, BRCA/HRD durumu, PARP inhibitörü maruziyeti, kalıcı toksisiteler ve hasta tercihi birlikte değerlendirilir. Platin kullanımı sırasında progresyon kanıtlanmışsa yeniden platin kullanımından beklenen yarar düşüktür; erken semptomatik progresyonda da direnç beklenebilir. Bu derleme, nüks epitelyal over kanserinde platinin yeniden kullanımına uygunluğu ve güncel tedavi seçeneklerini birlikte değerlendirmektedir.

 

Referanslar

González-Martín A, Harter P, Leary A, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(10):833-848. doi:10.1016/j.annonc.2023.07.011.

Chase DM, Patton G, Annavarapu S, et al. Predicting platinum-resistance in advanced ovarian cancer: defining patient and disease characteristics to improve treatment approaches at initiation of treatment or earlier in the course of the disease. Front Oncol. 2026;16:1765220. doi:10.3389/fonc.2026.1765220.

Wang Q, Kuang L, Liu B, et al. A real-world retrospective cohort study: the clinical outcomes and characteristics of platinum-resistant recurrent ovarian cancer. Transl Cancer Res. 2025;14(5):3161-3174. doi:10.21037/tcr-2025-641.

González-Martín A, Ledermann JA. ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer. ESMO Open. 2026;11(2):106032. doi:10.1016/j.esmoop.2025.106032.

Ji S, Chen L, Yu Y, et al. A comprehensive comparison of PARP inhibitors as maintenance therapy in platinum-sensitive recurrent ovarian cancer: a systematic review and network meta-analysis. J Ovarian Res. 2025;18:18. doi:10.1186/s13048-025-01599-1.

Toyohara Y, Yunokawa M, Nimura R, et al. Effect of first-line poly(ADP-ribose) polymerase inhibitor on second-line platinum-based chemotherapy in epithelial ovarian cancer. J Gynecol Oncol. 2026;37(4):e82. doi:10.3802/jgo.2026.37.e82.

Nag S, Ray-Coquard I, Gupta S, et al. Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer. ESMO Open. 2025;10(6):105125. doi:10.1016/j.esmoop.2025.105125.

Colombo N, Zsiros E, Parma G, et al. Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2026;407(10538):1525-1537. doi:10.1016/S0140-6736(26)00602-1.

Lorusso D, Gladieff L, O’Malley DM, et al. Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial. Lancet. 2026;407(10538):1513-1524. doi:10.1016/S0140-6736(26)00462-9.

Yuan G, Lou G, Li J, et al. Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial. Nat Cancer. 2026;7:182-193. doi:10.1038/s43018-025-01085-z.

Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-2045. doi:10.1200/JCO.2012.42.0505.

Harter P, Sehouli J, Vergote I, et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med. 2021;385(23):2123-2131. doi:10.1056/NEJMoa2103294.

Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302-1308. doi:10.1200/JCO.2013.51.4489.

Moore KN, Angelergues A, Konecny GE, et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med. 2023;389(23):2162-2174. doi:10.1056/NEJMoa2309169.

US Food and Drug Administration. FDA approves mirvetuximab soravtansine-gynx for FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. 22 March 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant-epithelial-ovarian (accessed 28 September 2026).

US Food and Drug Administration. FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. 10 February 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-paclitaxel-platinum-resistant-epithelial-ovarian-fallopian-tube-or (accessed 28 September 2026).

US Food and Drug Administration. FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. 25 March 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-relacorilant-nab-paclitaxel-platinum-resistant-epithelial-ovarian-fallopian-tube-or (accessed 28 September 2026).

Lesnock JL, Temin S, Bouberhan S, et al. Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0. J Clin Oncol. Published online July 13, 2026. doi:10.1200/JCO-26-01591.

Coleman RL, Spirtos NM, Enserro D, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019;381(20):1929-1939. doi:10.1056/NEJMoa1902626.

Jiang R, Zhu J, Kim JW, et al; SOC-1 Investigators. Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomised phase 3 trial. Nat Med. 2024;30(8):2181-2188. doi:10.1038/s41591-024-02981-0.

Yayınlanan

16 Kasım 2026

Lisans

Lisans